Investment Summary

Exits Paratek Pharmaceuticals

On July 24, 2013, invested in life science company Paratek Pharmaceuticals from Aisling Capital

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Massachusetts.
Investment Fate
  • Paratek Pharmaceuticals was sold to a financial buyer in 2022.

Investment Summary

Date 2013-07-24
Target Paratek Pharmaceuticals
Sector Life Science
Sellers(s) Aisling Capital
Deal Type IPO

Target

Paratek Pharmaceuticals

Boston, Massachusetts, United States
website
Paratek Pharmaceuticals is a bio-pharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek Pharmaceuticals was founded in 1996 and is based in Boston, Massachusetts.

Search 177,960 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Seller(S) 1

SELLER

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.


DEAL STATS #
Overall 21 of 35
Sector (Life Science) 18 of 26
Type (IPO) 2 of 9
State (Massachusetts) 2 of 2
Country (United States) 21 of 35
Year (2013) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-10 Loxo Oncology

Stamford, Connecticut, United States

Loxo Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is based in Stamford, Connecticut.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-05 IQVIA

Durham, North Carolina, United States

IQVIA is a provider of advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

Sell -